| Literature DB >> 30442097 |
Magda Zanelli1, Maria Cecilia Mengoli1, Rachele Del Sordo2, Angelo Cagini2, Loredana De Marco1, Edoardo Simonetti3, Giovanni Martino3, Maurizio Zizzo4,5, Stefano Ascani6.
Abstract
BACKGROUND: Intravascular lymphoma is a rare type of non-Hodgkin lymphoma mostly of B-cell lineage. A few cases of intravascular lymphoma have been found to be of NK/T-cell origin, mainly affecting the skin and central nervous system. CASEEntities:
Keywords: Epstein-Barr virus; Intravascular; Lymphoma; Natural killer cell; T-cell
Mesh:
Year: 2018 PMID: 30442097 PMCID: PMC6238309 DOI: 10.1186/s12885-018-5001-6
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1EBV DNA detection in pleural effusion by Polymerase chain reaction (PCR)
Fig. 2Haematoxylin and Eosin, medium power of view of the myocardium (a), of the brain (b) and liver parenchyma (c), show a prominent intravascular growth of neoplastic, pleomorphic cells without invasion of the organs parenchyma characteristic of intravascular lymphoma either of B or NK/T lineage. Immunohistochemistry with CD68 PGM1 (d) of the bone marrow evidence prominent features of haemophagocytotosis
Fig. 3Haematoxylin and Eosin, medium power of view of the lung parenchyma with striking features of growth of the neoplastic cells within the capillaries of the alveolar walls (a). Immunohistochemistry with CD3 (b), CD56 (c) and granzyme B (d) demonstrate a positive staining of the neoplastic intravascular cells. EBER (e) has been demonstrated also to be diffusely positive in this case of intravascular NK/T lymphoma
Fig. 4TCR assay provided molecular genetic evidence of clonality. One reproducible clonal peak is showed in TCR-G
Demographic data, clinical data, and characteristics of reported cases of IVL of T and NK-cell lineage
| Ref. | Age/sex | Sites involved at presentation/(symptoms/ signs) | Sites involved during disease course | BOM involvement | Immunophenotype | EBER | TCR | Therapy/outcome |
|---|---|---|---|---|---|---|---|---|
| Santucci 2003 [ | 54/M | Skin lesions, weight loss, leukopenia | CNS | NA | CD3e + CD56 + TIA-1 + GrB + CD30 + ki671 + 100%LMP1-CD4- CD8- CD20- CD79a- CD57- CD68- Bcl2- | + | NA | CHOP/Exitus 17 mo after diagnosis |
| Wu 2005 [ | 41/M | Skin lesions | none | – | CD3e + CD2 + CD7 + CD56 + CD43 + perforin+ TIA-1 + Bcl2 + CD20- CD4- CD8- CD5- TCRbF1- CD30- lysozyme- MPO- Keratin- | + | TCR germline | CHOP+ |
| Wu 2005 [ | 47/F | Fever, weakness, arthralgia, myalgia, mental signs+ pancytopenia | Disseminated disease at autopsy (brain, bone marrow, kidneys, ovaries, cervix) | + (diagnosis made on BOM biopsy) | CD3e + CD2 + CD7 + CD56 + GrB + TIA-1 + CD20- CD5- CD4- CD8- CD57- | – | TCR germline | Unspecified therapy/exitus 15 days after diagnosis |
| Kuo 2006 [ | 71/F | Skin lesions | none | – | CD3e + CD56 + TIA1 + KI67 + 90%CD4- CD5- CD8- CD10- CD20-CD30- BCL6- LMP-1- | + | TCR germline | No therapy/alive at 5 mo |
| Song 2007 | 40/F | Skin lesions+CNS | none | – | LCA + CD3 + CD56+ GrB + TIA + 1+ Ki67 + 100% | + | TCR germline | CODOX-M + IVAC/alive at 7mo |
| Nakamichi 2008 [ | 23/F | Skin lesions | Ileum, spleen+fever | – | CD3e + CD56+ | + | TCR germline | CHOP followed by PromMACE/CYTABOM, L-ASP/CY, hyper CVAD/MTX-AraC, SCT. Exitus after 9 mo, due to aGVHD |
| Cerroni 2008 [ | 67/F | Skin lesion+CNS | none | NA | CD2+ CD3e + CD8 + CD56-TIA-1 + CD4- CD20- CD30+/- CD56- | NA | TCR monoclonal (TCRg) | Exitus after 7 days |
| Cerroni 2008 [ | 63/M | Skin lesions+arthralgias, weight loss, fever, depression+leukopenia+ thrombocytopenia | none | NA | CD2 + CD3e + TIA1 + CD56+ CD4- CD5- CD7- CD8- CD20- CD45RO + bF1- | + | TCR germline | Exitus after 6 mo |
| Cerroni 2008 [ | 64/M | (History of B-CLL). Skin lesions | NA | - (B-CLL+) | CD2 + CD3e + TIA-1 + CD4- CD5- CD8- CD20- CD56- bF1- | – | TCR germline | CHOP, exitus after 7 mo |
| Cerroni 2008 [ | 87/M | Skin lesions+portal hyperthension | none | NA | CD2 + CD3e + CD56- TIA-1- GrB-perforin- CD4- CD5- CD7- CD8-CD20- CD30- CD45RO- bF1- | + | TCR monoclonal (TCRg) | Exitus after 15 days |
| Gleason 2008 [ | 62/M | Skin lesions+night sweats | none | – | LCA + CD2 + CD3e + CD43 + CD56 + Perforin+ GrB + TIA-1 + CD4- CD5- CD7- CD8- CD20- CD79a- BCL2- CD30- CD45RO- TCRbF1- TdT- MPO- CK- CD34- | – | TCR monoclonal(TCRg) | CHOP followed by DHAP. AWD at 8 mo |
| Liao 2011 [ | 42/F | Skin lesions+ malaise, dizziness. | none | – | CD3e + CD56 + Gr-B + KI67 + 99%,bF1- CD4- CD5- CD8- CD20- CD30- PAX5- TdT- | + | NA | RT + CT: (CHOP,Bortezomib, EPOCH); alive at 14 mo |
| Yanning 2013 | 84/F | Skin lesions+fever, weight loss | NA | NA | CD2 + CD3e + CD45RO + GrB + CD4- CD5- CD7- CD8- CD20- CD79a- CD56- CD30- panCK- | + | TCR germline | Therapy refused. AWD at 4 mo |
| Jang 2014 | 23/F | Skin lesions | none | – | CD3 + CD8 + GrB + TIA-1 + LCA + MPO + CD4- CD5- CD20- CD30- CD56- CK- | + | TCR germline | CHOP+intratecal MTX + PBSCT. |
| Liu 2014 | 38/F | Skin lesions | CNS | – | CD3 + CD56 + GrB + Ki67 + 90%CD4- CD5- CD8- CD20- CD30- PAX5- TdT- | + | NA | CHOP. After 7 mo recurrence at CNS. Exitus 13 mo after diagnosis |
| Wang 2015 | 45/M | Skin lesions+malaise, fever, weight loss | NA | NA | CD2 + CD3e + perforin+ GrB + TIA1 + CD56 + CD4- CD8- CD20- TCRb- TCRg- CD30- KI67 + 90–100% | + | TCR germline | Exitus 15 days after diagnosis |
| Wang 2015 | 32/F | Skin lesions+fever | none | NA | CD2 + CD3e + perforin+ GrB + TIA1 + CD56 + CD4- CD8- CD20- TCRb- TCRg- CD30- KI67 + 90–100% | + | TCR germline | CHOP. Exitus 4 mo after diagnosis |
| Wang 2015 | 18/F | Skin lesions | none | – | CD2 + CD3e + perforin+ GrB + TIA1 + CD56 + CD4- CD8- CD20- TCRb- TCRg- CD30 + KI67 + 90–100% | + | TCR germline | CHOP. Alive 3 yrs. after diagnosis |
| Bi 2015 | 29/M | Skin lesions, fever, weight loss | Liver | – | CD3 + CD43 + CD56 + TIA-1 + CD30 + CD4- CD5- CD7- CD8- CD20- CD79a- KI67 + 90% | + | TCR germline | HyperCVAD. Exitus 3 mo after diagnosis |
| Alhumidi 2015 | 48/F | Skin lesions | None | – | CD45 + CD3 + GrB + CD56- CD4- CD5- CD8- CD20- | + | NA | CT. Alive 18 mo after diagnosis |
| Jaffe 2017 | 51/M | Skin lesions+CNS | none | NA | CD3 + CD8 + TIA-1 + GrB + CD20- CD79a- CD56- ALK-1- | + | TCR monoclonal (TCR-g) | NA |
| Sharma 2017 | 62/F | CNS | none | + on molecular analysis (TCR) | CD3 + CD8 + CD57 + GrB + TIA-1 + CD2- CD4- CD5- CD7- CD30- CD56- TdT- PAX5- | – | TCR monoclonal | Methylprednisolone, dexamethasone, intratechal MTX, cytarabine. Exitus |
| Alegria-Landa 2017 | 81/M | Skin lesions | none | – | CD3 + GrB + perforin+ CD30 + CD20- CD4- CD8- TCRb- TCRg- CD56- | + | TCR monoclonal (TCRbTCRg) | Exitus 15 days after diagnosis |
| Present case | 54/M | Jaundice, fever, respiratory symptoms, pancytopenia. PB: no atypical lymphocytes | Disseminated disease at autopsy (brain, heart, kidney, lung, bone marrow) | + (subtle infiltration) | CD3 + CD2 + perforin+ GrB + CD56 + KI67 + 80% CD20- CD79a- PAX5- CD4- CD8- CD5- ALK1-CD16- | + | TCR monoclonal | Exitus 18 days after presentation |
Ffemale, M male, BOM bone marrow, NA not assessed, CR complete remission, mo months, yrs. years, B-CLL B chronic lymphocytic leukemia, RT radiotherapy, CT chemotherapy, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, SCT Stem cell transplant, CODOX-M cyclophosphamide, vincristine, doxorubicin, methotrexate, IVAC ifosfamide, mesna, etoposide, cytarabine, ProMACE/CytaBOM prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytosine, arabinoside, bleomycin, vincristine, leucovorin, l-ASP l-asparaginase, CY cyclophosphamide, hyper-CVAD hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, MTX methotrexate, AraC cytosine arabinoside, aGVHD acute graft-versus-host disease, EPOCH etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, DHAP dexamethasone, cytarabine, cisplatin, PBSCT peripheral blood stem-cell transplant, PB peripheral blood, AWD alive with disease